ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >protein tyrosine kinase >Amuvatinib

Amuvatinib

CAS No.: 850879-09-3

Chemical Name:: Amuvatinib

Synonyms: AMuvatinib;Mp470;HPK 56;CS-460;MP470;HPK 56;MP-470(MP 470);AMuvatinib (MP-470);MP-470 (Amuvatinib);MP470 AMUVATINIB (MP-470);MP470 (MP-470, Amuvatinib)

CBNumber:: CB02484967

Molecular Formula:: C23H21N5O3S

Molecular Weight:: 447.51

MOL File:: 850879-09-3.mol

Modify Date:: 2024/7/2 8:54:57

Request For Quotation

Amuvatinib Properties

Density	1.443
storage temp.	Store at -20°C
solubility	≥22.4 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
form	solid
color	White to off-white
CAS DataBase Reference	850879-09-3

SAFETY

Risk and Safety Statements

Symbol(GHS)

GHS07

Signal word

Warning

Hazard statements

H315-H319-H335

Precautionary statements

P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P321-P362+P364-P332+P313-P337+P313-P403+P233-P405-P501

NFPA 704

	0
2		0

Amuvatinib Chemical Properties,Uses,Production

Description

Amuvatinib (also known as MP-470 or 850879-09-3), is a multi-targeted inhibitor of receptor tyrosine kinases that inhibits c-Kit, platelet-derived growth factor receptor α (PDGFRα), and c-Met (IC50s = 10, 40, and 81 nM, respectively). It inhibits growth and induces apoptosis in prostate cancer cell lines, with additive effects achieved when combined with erlotinib . Amuvatinib sensitizes cancer cells to radiation and chemotherapeutic compounds, in part by inhibiting homologous recombination.

Uses

MP-470 (Amuvatinib) is a potent and multi-targeted inhibitor of c-KitD816H, PDGFαV561D and Flt3D835Y with IC50 of 10 nM, 40 nM and 81 nM, respectively.

Clinical Use

Amivantamab is the first drug approved by the FDA for the treatment of patients with NSCLC and EGFR exon 20 insertion mutations.

Mode of action

Μechanisticly, amuvatinib inhibits tyrosine kinase receptor KIT through occupying its ATP binding domain (IC50 < 0.1 μM) and disrupts DNA repair through suppression of homologous recombination protein Rad51 as well as synergistic effects in combination with double stranded DNA damaging agents.

References

1. Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines
2. Janssen submits supplemental biologics license application to the U.S. Food and Drug Administration seeking approval of RYBREVANT? (amivantamab-vmjw) in combination with chemotherapy for the first-line treatment of patients with locally advanced or metastatic EGFR exon 20 insertion mutation-positive non-small cell lung cancer. News release.
3. Raoul Tibes, Gil Fine, Gavin Choy, Sanjeev Redkar, Pietro Taverna, Aram Oganesian, Amarpao Sahai, Mohammad Azab and Anthony W. Tolcher. A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol (2013) 71: 463-471
4. Gavin Choy, Rajashree Joshi-Hangal, Aram Oganesian, Gil Fine, Scott Rasmussen, Joanne Collier, James Kissling, Amarpal Sahai, Mohammad Azab and Sanjeev Redkar. Saftety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers. Cancer Chemother Pharmacol (2012) 70: 183-190

Amuvatinib Preparation Products And Raw materials

Raw materials

Preparation Products

Amuvatinib Suppliers

Global( 132)Suppliers

Supplier	Tel	Country	ProdList	Advantage	Inquiry
CLEARSYNTH LABS LTD.	+91-22-45045900	Hyderabad, India	6351	58	Inquiry
A.J Chemicals	91-9810153283	New Delhi, India	6124	58	Inquiry
Capot Chemical Co.,Ltd.	571-85586718 +8613336195806	China	29798	60	Inquiry
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	China	32835	60	Inquiry
career henan chemical co	+86-0371-86658258 +8613203830695	China	29899	58	Inquiry
Chongqing Chemdad Co., Ltd	+86-023-6139-8061 +86-86-13650506873	China	39916	58	Inquiry
CONIER CHEM AND PHARMA LIMITED	+8618523575427	China	49403	58	Inquiry
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	United States	19892	58	Inquiry
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	China	23499	58	Inquiry
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	China	10522	58	Inquiry

Supplier	Advantage
CLEARSYNTH LABS LTD.	58
A.J Chemicals	58
Capot Chemical Co.,Ltd.	60
ATK CHEMICAL COMPANY LIMITED	60
career henan chemical co	58
Chongqing Chemdad Co., Ltd	58
CONIER CHEM AND PHARMA LIMITED	58
TargetMol Chemicals Inc.	58
Dideu Industries Group Limited	58
Zhejiang J&C Biological Technology Co.,Limited	58

Amuvatinib Spectrum

N-(1,3-Benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidin-4-yl-1-piperazinecarbothioamide(850879-09-3)¹HNMR

850879-09-3(Amuvatinib)Related Search:

Everolimus Axitinib SNS-032 Dasatinib Mocetinostat (MGCD0103)

Foretinib (GSK1363089)

chevron_left

1of2

chevron_right

N-(1,3-Benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidin-4-yl-1-piperazinecarbothioamide 1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro(3,2-D)pyrimidin-4-yl- Mp470 AMuvatinib HPK 56 MP-470(MP 470) AMuvatinib (MP-470) AMuvatinib (MP-470, HPK 56) MP470 AMUVATINIB (MP-470) MP 470 N-(1,3-Benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidin-4-yl-1-piperazinecarbothioamide N-(1,3-Benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidin-4-yl-1-piperazinecarbothioamide Amuvatinib(MP470 ) MP470 (MP-470, Amuvatinib) CS-460 MP-470 (Amuvatinib) MP-470; MP 470; MP470; HPK 56 N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro-[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioam N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide AMUVATINIB (MP-470);MP-470; MP 470; MP470; HPK 56 MP470;HPK 56 N-(1,3-Benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidin-4-yl-1-piperazinecarbothioamide USP/EP/BP 850879-09-3 Inhibitors Inhibitor